Cite
HARVARD Citation
Manno, D. et al. (2023). Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. Lancet infectious diseases. 23 (3), pp. 352-360. [Online].